News Gilead tags Merck for first-line triple negative breast canc... Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?
News Gilead scores US approval for breast cancer drug that wowed ... Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.